RxDoctor Payments Data

Stephen Fincher, MD

Internal Medicine · Tulsa, OKNPI 1952388555

Payments from drug & device makers

$452in general payments, 2019–2025

Across 22 payments — averaging $20.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Astellas Pharma US Inc$147
  • AbbVie$63
  • Novartis$39
  • Johnson & Johnson$31
  • Aimmune Therapeutics, Inc.$29
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$25
  • plus $118 from 7 others

What the payments were for

  • Food & beverage$452100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$452 in reported general payments places this provider in the 55th percentile of 840 internal medicine providers in Oklahoma.

See all internal medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$79,991
Medicare patients
309
Services billed
3,599

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban227$191,149
OzempicSemaglutide92$118,134
MounjaroTirzepatide100$105,726
JardianceEmpagliflozin109$94,248
XareltoRivaroxaban115$85,895
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$37,672
LinzessLinaclotide22$19,931
EntrestoSacubitril/Valsartan23$17,623
Rosuvastatin Calcium389$16,891
Atorvastatin Calcium474$13,133
OxycontinOxycodone Hcl13$10,283
Potassium Chloride258$9,442
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$8,919
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen285$8,118
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$7,552

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$19$118,13492 claims
Lilly USA, LLCMounjaro$16$105,726100 claims
Johnson & JohnsonXarelto$31$85,895115 claims
AbbVieLinzess, Synthroid$63$22,59265 claims
NovartisEntresto$39$17,62323 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 840 internal medicine providers in Oklahoma.

Other internal medicine in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →